A carregar...

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: al...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Expert Rev Anticancer Ther
Main Authors: Atallah, Ehab, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5176249/
https://ncbi.nlm.nih.gov/pubmed/19445582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.09.14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!